Burney Co/ 13F: Exits PTC Therapeutics (PTCT) Stake

Burney Co. has sold its entire stake in PTC Therapeutics, Inc. (PTCT) as detailed in its latest Form 13F filing on October 15, 2026. The fund cut 37,320 shares, leaving it with no remaining position in the company.

What Changed in Burney Co.'s PTC Position

Burney Co. has sold out its entire position in PTC Therapeutics, reducing its shares from 37,320 to 0. This represents a 100% decrease in its holdings. The decision reflects a significant shift in the fund's investment strategy regarding this particular stock.

Other Institutional Activity in PTC

Several other institutional players have remained active in PTC Therapeutics. Blackrock Inc. raised its stake by 1,016,428 shares, bringing its total to 13,964,554 shares worth about $827.3 million. Jupiter Topco LLC also increased its holdings by 3,618,201 shares, resulting in 7,236,402 shares valued at approximately $428.7 million. Vanguard Portfolio Management LLC added 123,479 shares, ending with 4,928,111 shares worth about $291.9 million, while State Street Corporation increased its holdings by 252,527 shares, reaching a total of 4,598,952 shares valued at about $272.4 million.

PTC Therapeutics, Inc. Stock Down 2.9%

Recently, PTC Therapeutics was trading at approximately $59.22 as of October 16, 2026. This price reflects a 12.6% decline below its 50-day moving average and a 17.2% decline below its 200-day moving average. The stock is currently about 34.8% lower than its 52-week high of $90.87, but it's slightly above its 52-week low of $58.80.

Recent Earnings

In the trailing twelve months, PTC Therapeutics reported revenue of approximately $1.01 billion, showcasing a 101.5% year-over-year growth. The company remains focused on developing treatments for rare disorders. The next earnings report is expected on October 29, 2026.

Insider Buying and Selling at PTC Therapeutics, Inc.

Insider transactions show mixed activity at PTC Therapeutics. On June 24, 2026, Chief Technical Officer Neil Gregory Almstead bought 5,323 shares at an average price of $38.10, valued at about $202,806. Later, on June 26, he sold 8,130 shares at an average price of $85.26, worth about $693,152. Another transaction on June 26 saw him buy 8,130 shares again at $38.10, totaling approximately $309,753. Recently, on October 9, 2026, Executive VP Mark Boulding sold 192 shares at $64.26, valued at about $12,338.

Analysts Set New Price Targets

Several analysts have maintained their ratings on PTC Therapeutics. On July 31, 2026, Morgan Stanley maintained an Overweight rating with a price target of $104, which was raised from $93. Wells Fargo followed suit, keeping its Overweight rating with a target of $109, increased from $106 on August 13, 2026. Barclays also maintained an Overweight rating, raising its target to $122 from $120 on August 14, 2026. Cantor Fitzgerald and RBC Capital also maintained Overweight and Sector Perform ratings, respectively, with price targets of $137 and $75.

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders. As of October 2026, the company's growth has been driven by its innovative approaches to treating these conditions, which is critical in a niche market.

Bottom Line

Investors should watch for further filings and updates from Burney Co. as the market reacts to PTC Therapeutics' upcoming earnings report on October 29, 2026. This 13F filing reflects past positions and may not represent current holdings, so further developments could impact investor sentiment.